Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Summary

This research study is studying the safety, tolerability, and tumor activity of the study drug known as rogaratinib as a possible treatment for bladder cancer.

Timeline

Start

2019-11-27

Primary completion

2019-11-27

Completion

2019-11-27

Outcome

Outcome not reported

Stopped: “Withdrawn per Bayer”

Drugs

Indications